SYDNEY, Australia, March 04, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in Oppenheimer’s 29th Annual Healthcare Conference.
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
|Conference:||Oppenheimer’s 29th Annual Healthcare Conference|
|Dates:||19 March 2019, from 9:10 AM to 9:40 AM Eastern Standard Time|
|Venue:||The Westin New York Grand Central, 212 East 42nd Street, New York, USA|
|Presenter:||Marc Voigt, CEO of Immutep|
The presentation is expected to be live webcasted. A link to the webcast will be made available on the Company’s website.
Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the US.
For further information please visit www.immutep.com or contact:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; firstname.lastname@example.org
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; email@example.com
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; firstname.lastname@example.org